Colorado Mycobacteria Conference 2016

Home » Meeting Agenda and Abstract Book

Meeting Agenda and Abstract Book

Format: There will be no concurrent sessions, allowing all participants to attend all proceedings. The three days of the conference will be organized according to research areas. Each day will be divided into talks, starting at 8:30 am, with a lunch break at noon followed by a short afternoon session. Oral presentations will be divided into longer presentations made by invited speakers and shorter presentations selected from the submitted abstracts. The mix of each type of talk will vary by day based on the decisions made by the selection committee for each day. Poster sessions on the topic of the day will be attended by presenters during the afternoon.

A downloadable version of the agenda can be found here.

 

Keynote Speakers, Tuesday Jun 7, 2016

Warwick Britton, M.D., Ph.D
Professor Britton is the Head of the Discipline of Infectious Diseases Immunology and the Mycobacterial Research Program in the Centenary Institute of Cancer Medicine Cell Biology, University of Sydney, Sydney, Australia. Professor Britton is a clinical immunologist, recognized as an international authority on the immunology of infectious diseases. After completing a PhD on the immunology of leprosy, he established the Mycobacterial Research Laboratory in Kathmandu, which continues as a major field center for the study of leprosy. He then joined Faculty of Medicine and is currently the Bosch Chair of Medicine and the Head of the Disciplines of Medicine and Infectious Diseases & Immunology in the Central Clinical School.

Gilla Kaplan, Ph.D.
Dr. Kaplan is a director at the Bill & Melinda Gates Foundation. She serves on the Board of the Celgene Corporation, chairs the Scientific Advisory Board of the Heiser Program for Research in Leprosy and Tuberculosis, and previously chaired the Board of the Desmond Tutu HIV Foundation. She is also a member of the Scientific Advisory Board of the Howard Hughes Medical Institute, University of KwaZulu-Natal Research Institute for Tuberculosis and HIV.


Agenda:

Tuesday, Jun 7, 2016 – Arrival Day

10:00 –          5K Fun Run (more information for participants here)

4:00 – 5:30    Registration (UCA)

5:00 – 5:15    Alan Rudolph, MBA, PhD, Vice President for Research, Colorado State University, Fort Collins, CO, “Welcome”.

5:15 – 6:15    Professor Warwick Britton, M.D., Ph.D., Bosch Professor of Immunology Medicine, Central Clinical School, Centenary Institute of Cancer Medicine & Cell Biology, University of Sydney, Sydney, Australia, “TB & Leprosy Research:  Then and Now”.

6:00 – 8:00    Happy Hour (UCA) Social Event

8:00 – 9:00    Professor Gilla Kaplan, Ph.D., Director, Tuberculosis Programs, Bill & Melinda Gates Foundation, Seattle, WA, “Filling the Gaps: The BMGF Approach to TB Research and Development”.

 

Wednesday, Jun 8, 2016 – Biochemistry/Physiology/Drug Development 

Chair: Dean Crick, Ph.D., Colorado State University, Fort Collins, CO

7:00 – 9:00      Registration (UCA)

8:15 – 8:30      Opening Comments

8:30 – 9:30      Kyu Rhee, MD, Ph.D., Weill Cornell Medical College, New York City, NY: “Mycobacterial Metabolism: Chemical Biology at the Intersection of Pathogen Biology and Drug Development”.

9:30 – 10:00    Joshua Thiede, Ph.D., Department of Microbiology and Immunology, Center for Infectious Diseases and Microbiology Translational Research, University of Minnesota, MN:  Potentiating the Anti-Tubercular Action of Antifolate Drugs”.

10:00 – 10:30  Break

10:30 – 11:00  Anna Upton, Ph.D., Director Biology, Global Alliance for TB Drug Development, New York City, NY: “In Search of a New Generation of Bedaquiline”.

11:00 – 12:00  Sir Tom Blundell FRS, FMedSci, Department of Biochemistry, University of Cambridge, Cambridge, UK: “Genomics, Structural Biology and Discovery of New Antimicrobials: Recent Developments with M. tuberculosis and M. abscessus”.

12:00 – 1:00   Lunch and Poster Set Up

Chair: Anne Lenaerts, Ph.D., Colorado State University, Fort Collins, CO

1:00 – 1:30      Martin Voskuil, Ph.D., University of Colorado School of Medicine, Aurora, CO: “Antibiotic Bactericidal Activity is Countered by Maintaining pH Homeostasis”.

1:30 – 2:00      Kristiana Santoso, Ph.D., Victoria University of Wellington, Wellington, New Zealand: “The Development of Type II NADH Dehydrogenase Inhibitors as Anti-Tuberculosis Drugs”.

2:00 – 3:00      Anura Rambukkana, Ph.D., Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, UK: “Harnessing Mycobacterial Ingenuity of Cell Reprograming: New Insights into Pathogenesis and Tissue Repair”.

3:00 – 5:00      Poster Session

5:00 – 6:00      Happy Hour, CooperSmith’s (Poolside)

6:00 –              Dinner, CooperSmith’s (Poolside)

 

Thursday, Jun 9, 2016 – Immunology/Immunopathology/Host-Pathogen

Chair: Diane Ordway, Ph.D., Colorado State University, Fort Collins, CO

7:00 – 8:00      Registration (UCA)

8:15 – 8:30      Opening Comments

8:30 – 9:30      Daniel Hoft, M.D., Ph.D., St. Louis University School of Medicine, St. Louis, MO: “The Role of Human Gamma9/Delta2 T Cells in TB Immunity”.

9:30 – 10:00    Angelo Izzo, Ph.D., Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO: “BCG?”.

10:00 – 10:30  Break

10:30 – 11:00  Brendan Podell, Ph.D., Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO: “Early Immune Responses in the Guinea Pig Model of Diabetes-Tuberculosis Comorbidity”.

11:00 – 12:00  Edward Chan, M.D., Denver Veterans Affairs Medical Center; National Jewish Health Center; University of Colorado School of Medicine,  Denver, CO: “Nicotine Impairs Macrophage Control of Mycobacterium tuberculosis by Binding to Nicotine Acetylcholine Receptor, Activating NFkappaB and Inhibiting Autophagy”.

12:00 – 1:00    Lunch

1:00 – 1:30      Bernadette Saunders, Ph.D., University of Technology Sydney, Sydney, Australia: “A Dominant-Negative Mutation in TNFR1 Results in Increased Susceptibility to Pulmonary Tuberculosis Infection”.

1:30 – 2:00      Mercedes Gonzalez Juarrero, Ph.D., Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO: “Preclinical studies of aerosolized  host directed therapy for TB treatment“.

2:00 – 3:00      Paula I. Fujiwara, M.D., M.P.H, Scientific Director, International Union Against Tuberculosis and Lung Disease (The Union), Paris, France: “Linking Research to the End TB Strategy — will we get there by 2035?”.

3:00 – 5:00      Poster Session

 

 

Friday, Jun 10, 2016 – Epidemiology/Diagnostics/Biomarkers

Chair: John Belisle, Ph.D., Colorado State University, Fort Collins, CO

8:15 – 8:30      Opening Comments

8:30 – 9:30      Gerhard Walzl, M.D., University of Stellenbosch, Cape Town, South Africa: “How close are we to biomarker-driven?”.

9:30 – 10:00     Bryna Fitzgerald, Ph.D., Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO: “A Novel Polyamine Catabolite Identified as a Urine Biomarker of TB Treatment Response”.

10:00 – 10:30  Break

10:30 – 11:00  Mark Schoenbaum, DMV, Ph.D., National Epidemiologist, Cattle Health Center of Veterinary Services of APHIS, USDA: “US Cattle TB eradication program: where is Mycobacterium bovis coming from now?”.

11:00 – 11:30  Kathy Orloski, DMV, MS, Diplomate, ACVPM (Epidemiology), Surveillance Design and Analysis Unit, Centers for Epidemiology and Animal Health, Veterinary Services, APHIS, USDA, “Changing the epidemiologic paradigm at the human animal interface: using whole genome sequencing to track Mycobacteria bovis infection across species”.

11:30 – 12:00  Adrian Muwonge, Ph.D., Division of Genomics and Genetics, The Roslin Institute, University of Edinburgh, Edinburgh, UK: “Predicting Cattle Movement Networks: Mycobacterium bovis Spatial-Genotyping Versus Gravity Modelling”.

12:00 – 1:00    Lunch

Chair: Francisco Olea-Popelka, D.V.M., Colorado State University, Fort Collins, CO

1:00 – 2:00      Michael Strong, Ph.D., National Jewish Health, Denver, CO: “Nontuberculous mycobacteria impacting individuals with or without Cystic Fibrosis: Genomic, Computational, and Epidemiologic Approaches”.

2:00 – 3:00      Stacey Martiniano, M.D., Department of Pediatrics, University of Colorado School of Medicine, Denver, CO: “Diagnosis and Treatment of NTM Infection in Cystic Fibrosis

3:00 ­- 3:30       Closing Comments

%d bloggers like this: